| Literature DB >> 35935046 |
Mehdi Hadjianfar1, Dariush Semnani1, Jaleh Varshosaz2, Sajad Mohammadi3, Sayed Pedram Rezazadeh Tehrani1.
Abstract
Purpose: 5-Fluorouracil (5FU) and Fe3O4 nanoparticles were encapsulated in core-shell polycaprolactone (PCL)/chitosan (CS) nanofibers as a multi-mode anticancer system to study drug release sustainability. The structure of the core-shell drug delivery system was also optimized according to drug release behavior by artificial intelligence.Entities:
Keywords: Artificial intelligence; Chitosan; Drug delivery systems; Fluorouracil; Magnetic field therapy; Nanofibers
Year: 2021 PMID: 35935046 PMCID: PMC9348528 DOI: 10.34172/apb.2022.060
Source DB: PubMed Journal: Adv Pharm Bull ISSN: 2228-5881
Design of experiment of drug release system
|
|
|
|
|
|
|
| C1 | 1.25 | 2:1 | 1 | 3 | 0 |
| C2 | 1.25 | 2:1 | 3 | 1 | 400 |
| C3 | 1.25 | 2:1 | 7 | 5 | 300 |
| C4 | 1.25 | 1:1 | 1 | 5 | 400 |
| C5 | 1.25 | 1:1 | 3 | 3 | 300 |
| C6 | 1.25 | 1:1 | 7 | 1 | 0 |
| C7 | 1.25 | 1:2 | 1 | 1 | 300 |
| C8 | 1.25 | 1:2 | 3 | 5 | 0 |
| C9 | 1.25 | 1:2 | 7 | 3 | 400 |
| C10 | 2 | 2:1 | 1 | 1 | 400 |
| C11 | 2 | 2:1 | 3 | 5 | 300 |
| C12 | 2 | 2:1 | 7 | 3 | 0 |
| C13 | 2 | 1:1 | 1 | 5 | 0 |
| C14 | 2 | 1:1 | 3 | 3 | 400 |
| C15 | 2 | 1:1 | 7 | 1 | 300 |
| C16 | 2 | 1:2 | 1 | 3 | 300 |
| C17 | 2 | 1:2 | 3 | 1 | 0 |
| C18 | 2 | 1:2 | 7 | 5 | 400 |
Morphology and tensile properties of core-shell nanofibers mat
|
|
|
|
|
| ||
|
|
|
| ||||
| C1 | 468±140 | 951±5 | 219±4 | 3.48±0.77 | 59.56±16.78 | 35.27±5.99 |
| C2 | 382±150 | 622±6 | 227±3 | 6.01±2.19 | 72.61±30.70 | 32.07±8.53 |
| C3 | 398±103 | 805±4 | 247±5 | 10.88±1.27 | 79.01±6.34 | 78.24±8.57 |
| C4 | 397±113 | 1307±7 | 357±4 | 6.59±0.37 | 63.90±4.08 | 58.45±3.27 |
| C5 | 347±92 | 935±5 | 367±5 | 9.29±1.81 | 85.46±7.95 | 60.26±6.40 |
| C6 | 290±217 | 546±7 | 382±7 | 7.69±1.06 | 75.06±3.62 | 63.29±1.61 |
| C7 | 311±64 | 1166±6 | 638±6 | 7.05±0.59 | 72.81±10.69 | 63.49±8.76 |
| C8 | 305±66 | 1317±5 | 661±4 | 10.34±1.58 | 57.36±5.53 | 76.06±3.60 |
| C9 | 272±51 | 831±5 | 686±5 | 7.35±1.51 | 38.87±6.62 | 87.12±2.16 |
| C10 | 392±108 | 767±6 | 214±5 | 7.95±1.17 | 111.78±7.12 | 36.41±4.48 |
| C11 | 419±102 | 990±5 | 234±6 | 6.62±0.65 | 111.04±7.31 | 36.35±7.17 |
| C12 | 401±93 | 621±6 | 244±4 | 5.72±1.25 | 71.53±17.13 | 42.95±3.79 |
| C13 | 410±121 | 1309±4 | 359±3 | 6.46±1.75 | 57.95±2.73 | 50.52±1.76 |
| C14 | 403±127 | 938±3 | 369±6 | 8.82±1.31 | 55.20±7.02 | 51.57±4.97 |
| C15 | 399±79 | 544±7 | 380±6 | 6.95±0.24 | 66.73±5.38 | 55.67±3.42 |
| C16 | 349±89 | 1350±6 | 643±7 | 4.98±0.82 | 78.39±6.37 | 60.77±2.03 |
| C17 | 340±93 | 949±5 | 669±5 | 5.52±2.34 | 63.49±5.62 | 69.13±5.60 |
| C18 | 378±140 | 1014±6 | 692±6 | 4.86±0.68 | 47.15±7.18 | 71.20±4.07 |
Figure 1Drug loading efficiency and coefficients of the mathematical models
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
| |
| C1 | 3 | 61.92±1.80 | 0.34 | 0.16 | 0.97 | 46.7 | 0.24 | 0.96 |
| C2 | 1 | 64.45±1.37 | 0.36 | 0.14 | 0.98 | 53.4 | 0.22 | 0.96 |
| C3 | 5 | 65.91±1.42 | 0.37 | 0.14 | 0.97 | 38.9 | 0.23 | 0.96 |
| C4 | 5 | 64.99±1.19 | 0.39 | 0.13 | 0.98 | 35.7 | 0.22 | 0.97 |
| C5 | 3 | 67.40±1.08 | 0.39 | 0.13 | 0.99 | 35.9 | 0.21 | 0.98 |
| C6 | 1 | 72.19±1.71 | 0.39 | 0.14 | 0.98 | 30.5 | 0.23 | 0.98 |
| C7 | 1 | 78.65±1.27 | 0.39 | 0.14 | 0.99 | 25.0 | 0.24 | 0.99 |
| C8 | 5 | 81.43±1.60 | 0.40 | 0.15 | 0.99 | 18.9 | 0.26 | 0.98 |
| C9 | 3 | 83.56±1.33 | 0.42 | 0.14 | 0.98 | 15.2 | 0.26 | 0.98 |
| C10 | 1 | 65.29±1.22 | 0.36 | 0.15 | 0.98 | 37.3 | 0.24 | 0.99 |
| C11 | 5 | 66.47±0.94 | 0.38 | 0.14 | 0.99 | 31.6 | 0.23 | 0.99 |
| C12 | 3 | 69.36±1.25 | 0.38 | 0.14 | 0.97 | 34.8 | 0.22 | 0.97 |
| C13 | 5 | 68.76±1.39 | 0.39 | 0.12 | 0.94 | 39.8 | 0.21 | 0.91 |
| C14 | 3 | 73.26±1.11 | 0.40 | 0.13 | 0.98 | 32.0 | 0.22 | 0.97 |
| C15 | 1 | 77.21±2.16 | 0.41 | 0.13 | 0.97 | 24.4 | 0.22 | 0.96 |
| C16 | 3 | 80.14±1.94 | 0.43 | 0.12 | 0.98 | 18.9 | 0.22 | 0.97 |
| C17 | 1 | 83.49±2.08 | 0.43 | 0.13 | 0.98 | 14.6 | 0.25 | 0.98 |
| C18 | 5 | 86.14±1.05 | 0.44 | 0.14 | 0.98 | 12.7 | 0.26 | 0.97 |
Figure 2MSE and R2 for cross validation and Gaussian noise methods
|
|
|
|
| Cross validation (k = 10) | 0.0128 | 0.954 |
| Gaussian noise method (µ = 0, SD = 0.05) | 0.0062 | 0.979 |
MSE, mean square error.
Figure 3
Figure 4
Figure 5Release parameters of optimized nanofibers
|
|
|
|
|
|
| |||||
|
|
| |||||||||
|
|
|
|
|
|
| |||||
| 7.4 | 78.22 | 144 | 34.41 | 81.48 | 0.42 | 0.13 | 0.99 | 20.6 | 0.23 | 0.99 |
| 4.4 | 74.87 | 72 | 35.74 | 0.45 | 0.12 | 0.97 | 16.8 | 0.20 | 0.97 | |
| ANN estimation | 86.22 | 141 | 36.07 | 86.22 | - | - | - | - | - | - |
| Error, % | 10.65 | 2.08 | 4.82 | 5.82 | - | - | - | - | - | - |
Figure 6
Figure 7